We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Gefitinib/Gemcitabine Better Tolerated Than Gefitinib/Vinorelbine by Elderly Patients With Advanced NSCLC

Jan 1, 2005
Volume: 
14
Issue: 
1
  • Lung Cancer

TORINO, Italy-Combination
therapy with gefitinib (Iressa) and
gemcitabine (Gemzar) produced disease
control in 45.7% of elderly patients
with advanced non-small-cell
lung cancer (NSCLC), according to
Giorgio V. Scagliotti, MD, of the University
of Turin, Torino, Italy, reporting
results of a phase II Italian
multicenter study (abstract 7081). The
study also found that patients were
better able to tolerate gefitinib/gemcitabine
than a gefitinib/vinorelbine
(Navelbine) combination.

The study included 59 elderly patients
with chemonaive stage IIIB/IV
NSCLC. All patients were treated with
gefitinib (250 mg/day orally until progression),
plus either vinorelbine
(30 mg/m2 IV, arm A) or gemcitabine
(1,200 mg/m2 IV, arm B). For unexplained
reasons, the two study arms
differed in a number of characteristics.
Male patients accounted for 58%
of arm A vs 80% of arm B, and squamous
histology characterized 17% of
arm A vs 31% of arm B.

Drugs were given on days 1 and 8
every 21 days for six cycles. The primary
endpoint was response rate.

Arm A was closed after 21 of the
first 24 patients (87.5%) had grade 3
or 4 adverse events, Dr. Scagliotti re
ported. These included 72% grade 3
or 4 neutropenia and treatment-related
deaths (one sudden cardiac arrest,
one grade 4 neutropenia with septic
shock
and cerebral infarction, and one
grade 4 diarrhea followed by cardiac
arrest).

"Of the 12 nonevaluable patients, 6
had withdrawn from the study, 5 had
died, and 1 had an unconfirmed diagnosis
of NSCLC," Dr. Scagliotti said.

In both arms, the most common
gefitinib-related adverse event was skin
toxicity, mainly grade 1-2. In arm B,
11.4% of patients experienced grade 3-
4 neutropenia and 8.6% had thrombocytopenia
, compared with 0 in arm A.
Grade 3-4 asthenia and diarrhea were
more common in arm A, with both
those adverse events occurring among
12% in arm A vs 5.7% in arm B. Dr.
Scagliotti also reported one case of grade
4 elevated transaminase levels.

Responses and Duration

Among the 27 patients in arm A
(gefitinib/vinorelbine) 1 (4%) had a
complete response (CR), 3 (12%) had
partial responses (PR), 7 (28%) had
stable disease (SD), 6 had progressive
disease (PD), and 7 patients were not
evaluable (see Table 1). Median duration
of response on arm A was 274
days; median time to progression
(TTP) was 91 days; median survival
was 371 days; and 63% of patients
were alive at 6 months.

Responses and Duration
Among the 27 patients in arm A
(gefitinib/vinorelbine) 1 (4%) had a
complete response (CR), 3 (12%) had
partial responses (PR), 7 (28%) had
stable disease (SD), 6 had progressive
disease (PD), and 7 patients were not
evaluable (see Table 1). Median duration
of response on arm A was 274
days; median time to progression
(TTP) was 91 days; median survival
was 371 days; and 63% of patients
were alive at 6 months.

"In elderly patients with advanced
NSCLC, vinorelbine plus gefitinib was
active but toxicity was unacceptable,
while gemcitabine plus gefitinib was
safe, and a remarkable percentage of
patients achieved disease control," Dr.
Scagliotti concluded.

Related Articles

  • Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer
  • New Option in NSCLC With IL-15 Agonist Plus Immune Checkpoint Inhibition
  • Durable Responses, Longer Survival Seen in NSCLC With Nivolumab at 5 Years

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.